Novel FDA Drug Approvals 2025

2025 marks a landmark year for regulatory science and therapeutic innovation.
The FDA has approved 45 novel drugs, with 2 additional therapies awaiting final approval, spanning oncology, rare diseases, infectious diseases, cardiology, neurology, nephrology, and immunology. These approvals reflect breakthroughs across ADCs, siRNA, ASOs, bispecific antibodies, kinase inhibitors, and first-in-class small molecules.

🔬 Oncology & Hematology Breakthroughs

Targeted therapies and next-generation biologics continue to redefine cancer care:

• Datopotamab deruxtecan 💉 – Antibody–drug conjugate (ADC) for breast cancer

• Treosulfan 💉 – DNA alkylator with fludarabine for allo-HSCT in AML

• Mirdametinib 💊 – MEK1/2 inhibitor for NF1

• Vimseltinib 💊 – CSF1R kinase inhibitor for solid tumors

• Penpulimab 💉 – PD-1 mAb for nasopharyngeal carcinoma

• Avutometinib + Defactinib 💊 – Dual therapy for KRAS-mutated serous ovarian cancer

• Telisotuzumab vedotin 💉 – c-MET–directed ADC for NSCLC

• Taletrectinib 💊 – ROS1 / NTRK inhibitor for NSCLC

• Sunvozertinib 💊 – EGFR-targeted TKI for NSCLC

• Zongertinib 💊 – Next-gen TKI for NSCLC

• Imlunestrant 💊 – ER antagonist/degrader for breast cancer

• Ziftomenib 💊 – Menin inhibitor for AML

• Sevabertinib 💊 – HER2 kinase inhibitor for NSCLC

• Linvoseltamab 💉 – Bispecific mAb for multiple myeloma

• Keytruda Qlex 💉 – PD-1 mAb lifecycle expansion

• Dordaviprone 💊 – Protease inhibitor for glioma

🧬 Rare & Genetic Diseases

Precision medicine shines in ultra-rare and inherited conditions:

• Fitusiran 💉 – Antithrombin-targeting siRNA for hemophilia A/B

• Elamipretide 💉 – Mitochondrial cardiolipin binder for Barth syndrome

• Doxecitine / Doxribtimine 💊 – For thymidine kinase 2 deficiency

• Sepiapterin 💊 – PAH activator for PKU

• Plozasiran 💉 – siRNA to lower triglycerides in familial chylomicronemia syndrome (FCS)

Immunology, Allergy & Inflammation

Novel pathways deliver disease-modifying options:

• Garadacimab 💉 – Factor XII mAb for HAE prophylaxis

• Sebetralstat 💊 – Plasma kallikrein inhibitor for acute HAE

• Donidalorsen 💉 – ASO for hereditary angioedema

• Remibrutinib 💊 – BTK inhibitor for chronic urticaria

• Rilzabrutinib 💊 – BTK inhibitor for ITP

• Depemokimab 💉 – IL-5 antagonist for asthma

• Brensocatib 💊 – DPP1 inhibitor for neutrophilic lung disease

• Delgocitinib 🧴 – Topical JAK inhibitor for eczema

🧠 Neurology, Cardiology & Pain

• Suzetrigine 💊 – Nav1.8 inhibitor for acute pain

• Aficamten 💊 – Cardiac myosin inhibitor for obstructive HCM

• Etripamil 👃 – Intranasal Ca-channel blocker for PSVT

• Nipocalimab 💉 – FcRn-binding mAb for myasthenia gravis

🦠 Anti-Infectives & Preventive Therapies

• Gepotidacin 💊 – DNA gyrase/topoisomerase IV inhibitor for UTI & gonorrhea

• Zoliflodacin 💊 – First-in-class antibiotic for gonorrhea

• Clesrovimab 💉 – RSV fusion protein mAb for infant passive immunity

👁️ Ophthalmology & Women’s Health

• Acoltremon 👁️ – TRPM8 activator for dry eye disease

• Aceclidine 👁️ – Muscarinic agonist for presbyopia

• Elinzanetant 💊 – NK-1/3 antagonist for menopausal symptoms

🩺 Nephrology & Metabolism

• Atrasentan 💊 – Endothelin A receptor antagonist for IgA nephropathy

• Sibeprenlimab 💉 – Proteinuria-reducing mAb for IgAN

• Narsoplimab 💉 – Anti-MASP-2 mAb for IgA nephropathy

• Lerodalcibep 💉 – PCSK9 inhibitor for hypercholesterolemia

• Nerandomilast 💊 – PDE4 inhibitor for idiopathic pulmonary fibrosis

• Paltusotine 💊 – Somatostatin receptor agonist for acromegaly

🔮 Takeaway

The 2025 FDA approvals highlight a decisive shift toward precision, durability, and first-in-class mechanisms. From siRNA and bispecific antibodies to targeted kinase inhibitors and novel antibiotics, this year’s cohort underscores how rapidly translational science is reshaping clinical practice.